Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study

<div>Kaplan-Meier cumulative probability of thrombotic event-free survival in recipients of dabigatran (DAB) and vitamin K antagonist (VKA) treatment.</div>

BioMed Research International

fig2

Figure 2

Figure 2: Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study 

Figure 2 | Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study 